Most cited papers from Susan Thompson Buffett Foundation
What are the most cited papers from Susan Thompson Buffett Foundation?
The most cited paper from Susan Thompson Buffett Foundation is "Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology" (Al B. Benson et al., 2021), with 1,789 citations. Next come "Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology" (1,772) and "Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology" (1,628).
Showing 50 of 60 papers. Every paper with more than 346 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | Mar 2021 | 1,789 |
| 2 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network | Feb 2022 | 1,772 |
| 3 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Apr 2020 | 1,628 |
| 4 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology James Lloyd Mohler et al. · Journal of the National Comprehensive Cancer Network | May 2019 | 1,580 |
| 5 | Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | May 2022 | 1,453 |
| 6 | Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology David G. Pfister et al. · Journal of the National Comprehensive Cancer Network | Jul 2020 | 1,406 |
| 7 | Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Margaret A. Tempero et al. · Journal of the National Comprehensive Cancer Network | Apr 2021 | 1,340 |
| 8 | Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Margaret von Mehren et al. · Journal of the National Comprehensive Cancer Network | Jul 2022 | 1,188 |
| 9 | Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Mary B. Daly et al. · Journal of the National Comprehensive Cancer Network | 6 Jan 2021 | 1,130 |
| 10 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network | Jul 2019 | 1,106 |
| 11 | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | May 2021 | 1,068 |
| 12 | Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Margaret A. Tempero et al. · Journal of the National Comprehensive Cancer Network | Aug 2017 | 1,046 |
| 13 | NCCN Guidelines Insights: Colon Cancer, Version 2.2018 Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | Apr 2018 | 1,045 |
| 14 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | Mar 2021 | 1,017 |
| 15 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | Dec 2019 | 1,009 |
| 16 | Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Jun 2022 | 981 |
| 17 | Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Michelle B. Riba et al. · Journal of the National Comprehensive Cancer Network | Oct 2019 | 892 |
| 18 | Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | Oct 2022 | 863 |
| 19 | Non–Small Cell Lung Cancer, Version 4.2024 Gregory J. Riely et al. · Journal of the National Comprehensive Cancer Network | May 2024 | 838 |
| 20 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | Mar 2016 | 739 |
| 21 | Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Deborah Kay Armstrong et al. · Journal of the National Comprehensive Cancer Network | Feb 2021 | 737 |
| 22 | Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Robert John Motzer et al. · Journal of the National Comprehensive Cancer Network | 2022 | 676 |
| 23 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Mary B. Daly et al. · Journal of the National Comprehensive Cancer Network | 31 Dec 2016 | 664 |
| 24 | Prostate Cancer, Version 1.2016 James Lloyd Mohler et al. · Journal of the National Comprehensive Cancer Network | 2016 | 657 |
| 25 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology Margaret R O'Donnell et al. · Journal of the National Comprehensive Cancer Network | Jul 2017 | 656 |
| 26 | Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Jul 2024 | 653 |
| 27 | NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018 Alexander Dimitrios Colevas et al. · Journal of the National Comprehensive Cancer Network | May 2018 | 642 |
| 28 | Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology Thomas W. Flaig et al. · Journal of the National Comprehensive Cancer Network | Mar 2020 | 638 |
| 29 | Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology Douglas E. Wood et al. · Journal of the National Comprehensive Cancer Network | Apr 2018 | 633 |
| 30 | Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Robert A. Swarm et al. · Journal of the National Comprehensive Cancer Network | Aug 2019 | 626 |
| 31 | Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Manisha H. Shah et al. · Journal of the National Comprehensive Cancer Network | Jul 2021 | 624 |
| 32 | Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology Edward Matthew Schaeffer et al. · Journal of the National Comprehensive Cancer Network | Oct 2023 | 604 |
| 33 | Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology Burt Nabors et al. · Journal of the National Comprehensive Cancer Network | Nov 2020 | 581 |
| 34 | Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network | Apr 2023 | 570 |
| 35 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology John A. Thompson et al. · Journal of the National Comprehensive Cancer Network | 11 Mar 2019 | 567 |
| 36 | NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022 Jimmy J. Caudell et al. · Journal of the National Comprehensive Cancer Network | Mar 2022 | 549 |
| 37 | NCCN Guidelines Insights: Breast Cancer, Version 1.2017 William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Apr 2017 | 545 |
| 38 | NCCN Guidelines Insights: Prostate Cancer, Version 1.2021 Edward Matthew Schaeffer et al. · Journal of the National Comprehensive Cancer Network | Feb 2021 | 532 |
| 39 | Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Robert I. Haddad et al. · Journal of the National Comprehensive Cancer Network | Aug 2022 | 525 |
| 40 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 Mary Beryl Daly et al. · Journal of the National Comprehensive Cancer Network | Apr 2020 | 516 |
| 41 | NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | Apr 2023 | 509 |
| 42 | NCCN Guidelines Insights: Rectal Cancer, Version 6.2020 Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | Jul 2020 | 508 |
| 43 | Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Apar Kishor Ganti et al. · Journal of the National Comprehensive Cancer Network | Dec 2021 | 493 |
| 44 | NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020 John A. Thompson et al. · Journal of the National Comprehensive Cancer Network | Mar 2020 | 493 |
| 45 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | Jul 2018 | 472 |
| 46 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Jun 2023 | 461 |
| 47 | Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Timothy D. Gilligan et al. · Journal of the National Comprehensive Cancer Network | Dec 2019 | 454 |
| 48 | Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology Daniel G. Coit et al. · Journal of the National Comprehensive Cancer Network | Apr 2019 | 440 |
| 49 | Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology John A. Thompson et al. · Journal of the National Comprehensive Cancer Network | Apr 2022 | 429 |
| 50 | Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Martin S. Tallman et al. · Journal of the National Comprehensive Cancer Network | Jun 2019 | 427 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.